These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33207828)

  • 21. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.
    López-Sendón Moreno JL; García Caldentey J; Trigo Cubillo P; Ruiz Romero C; García Ribas G; Alonso Arias MA; García de Yébenes MJ; Tolón RM; Galve-Roperh I; Sagredo O; Valdeolivas S; Resel E; Ortega-Gutierrez S; García-Bermejo ML; Fernández Ruiz J; Guzmán M; García de Yébenes Prous J
    J Neurol; 2016 Jul; 263(7):1390-400. PubMed ID: 27159993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects.
    Önnestam K; Nilsson B; Rother M; Rein-Hedin E; Bylund J; Anderer P; Kemethofer M; Halldin MM; Sandin J; Segerdahl M
    J Prev Alzheimers Dis; 2023; 10(4):778-789. PubMed ID: 37874100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
    Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
    Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
    CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease.
    Martinez-Horta S; Perez-Perez J; van Duijn E; Fernandez-Bobadilla R; Carceller M; Pagonabarraga J; Pascual-Sedano B; Campolongo A; Ruiz-Idiago J; Sampedro F; Landwehrmeyer GB; ; Kulisevsky J
    Parkinsonism Relat Disord; 2016 Apr; 25():58-64. PubMed ID: 26898966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphisms in the oxytocin receptor and their association with apathy and impaired social cognition in Huntington's disease.
    Saiz-Rodríguez M; Gil-Polo C; Diez-Fairen M; Martinez-Horta SI; Sampedro Santalo F; Calvo S; Alonso-García E; Riñones-Mena E; Aguado L; Mariscal N; Muñoz-Siscart I; Piñeiro D; Rivadeneyra J; Cubo E
    Neurol Sci; 2022 Oct; 43(10):6079-6085. PubMed ID: 35725858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of Apathy in Huntington's Disease and Other Movement Disorders.
    Krishnamoorthy A; Craufurd D
    Curr Treat Options Neurol; 2011 Oct; 13(5):508-19. PubMed ID: 21800056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Riluzole in Huntington's disease: a 3-year, randomized controlled study.
    Landwehrmeyer GB; Dubois B; de Yébenes JG; Kremer B; Gaus W; Kraus PH; Przuntek H; Dib M; Doble A; Fischer W; Ludolph AC;
    Ann Neurol; 2007 Sep; 62(3):262-72. PubMed ID: 17702031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Excessive response to provocation rather than disinhibition mediates irritable behaviour in Huntington's disease.
    McLauchlan DJ; Linden DEJ; Rosser AE
    Front Neurosci; 2022; 16():993357. PubMed ID: 36643017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot study using nabilone for symptomatic treatment in Huntington's disease.
    Curtis A; Mitchell I; Patel S; Ives N; Rickards H
    Mov Disord; 2009 Nov; 24(15):2254-9. PubMed ID: 19845035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Neuropsychiatry of Huntington Disease-Like 2: A Comparison with Huntington's Disease.
    Ferreira-Correia A; Krause A; Anderson DG
    J Huntingtons Dis; 2020; 9(4):325-334. PubMed ID: 33044188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.
    Ferreira JJ; Rosser A; Craufurd D; Squitieri F; Mallard N; Landwehrmeyer B
    Mov Disord; 2015 Sep; 30(10):1426-9. PubMed ID: 26175332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.
    Goadsby PJ; Dodick DW; Ailani J; Trugman JM; Finnegan M; Lu K; Szegedi A
    Lancet Neurol; 2020 Sep; 19(9):727-737. PubMed ID: 32822633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and genetic characteristics in patients with Huntington's disease from China.
    Yang J; Chen K; Wei Q; Chen Y; Cao B; Burgunder JM; Shang HF
    Neurol Res; 2016 Oct; 38(10):916-20. PubMed ID: 27483361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Huntington's Disease: Prevalence and Psychological Indicators of Pain.
    Underwood M; Bonas S; Dale M;
    Mov Disord Clin Pract; 2017; 4(2):198-204. PubMed ID: 30363479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial.
    Fernandez HH; Weintraub D; Macklin E; Litvan I; Schwarzschild MA; Eberling J; Videnovic A; Kenney CJ;
    Parkinsonism Relat Disord; 2023 Sep; 114():105511. PubMed ID: 37532622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing Mental Health Difficulties of Persons With Huntington's Disease: Does Informant Presence Make a Difference?
    Gunn S; Maltby J; Dale M
    J Neuropsychiatry Clin Neurosci; 2020; 32(3):244-251. PubMed ID: 32102601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.